News|Articles|May 18, 2020

EU Member States Meet to Discuss Drug Shortages During COVID-19

The EU Executive Steering Group on Shortages of Medicines Caused by Major Events met on May 13, 2020 to discuss measures the European Union is taking to ensure the availability of medicines during the COVID-19 pandemic.

The European Medicines Agency (EMA) announced on May 15, 2020 that the EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a virtual meeting on May 13, 2020 to discuss actions taken by authorities in the European Union to ensure the availability of medicines in Europe during the COVID-19 pandemic. The meeting included heads of national competent authorities (NCAs) of the EU Member States.

The continued roll out of the i-SPOC system was discussed during the meeting. The system allows industry to notify EMA and EU Member States of current or anticipated shortages of drugs crucial to the pandemic. Improvement of the supply of drugs used in intensive care units (ICUs) was discussed due to reported shortages of ICU medicines. Participants discussed the development of joint principles for assessing demand at the national level. The sharing of demand data by the NCAs was determined to be useful to ensure supply of ICU medicines. Information on models currently in use by some Member States was shared, and ways of improving forecasting capacities and data modeling best practices were discussed.

Source: EMA


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.